Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Helicases | 7 | 2025 | 136 | 1.730 |
Why?
|
| DNA-Binding Proteins | 7 | 2025 | 1482 | 1.220 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2025 | 97 | 0.840 |
Why?
|
| Colorectal Neoplasms | 4 | 2025 | 868 | 0.780 |
Why?
|
| Molecular Targeted Therapy | 2 | 2025 | 440 | 0.730 |
Why?
|
| Neoplasms | 5 | 2025 | 2913 | 0.640 |
Why?
|
| Cell Plasticity | 1 | 2021 | 37 | 0.640 |
Why?
|
| Clonal Evolution | 1 | 2020 | 47 | 0.610 |
Why?
|
| Spheroids, Cellular | 1 | 2020 | 74 | 0.600 |
Why?
|
| Antineoplastic Agents | 4 | 2025 | 2219 | 0.570 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 375 | 0.520 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2025 | 220 | 0.500 |
Why?
|
| Breast Neoplasms | 3 | 2025 | 2393 | 0.470 |
Why?
|
| Drug Synergism | 2 | 2025 | 354 | 0.410 |
Why?
|
| Cell Line, Tumor | 9 | 2025 | 3551 | 0.390 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2025 | 218 | 0.360 |
Why?
|
| Cell Survival | 2 | 2024 | 1103 | 0.290 |
Why?
|
| DNA Damage | 3 | 2024 | 437 | 0.240 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2025 | 23 | 0.230 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 133 | 0.220 |
Why?
|
| TCF Transcription Factors | 2 | 2020 | 19 | 0.190 |
Why?
|
| Drug Discovery | 2 | 2022 | 153 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 936 | 0.170 |
Why?
|
| Carbon Monoxide | 2 | 2018 | 82 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 883 | 0.150 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2019 | 24 | 0.150 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2022 | 258 | 0.150 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2022 | 273 | 0.140 |
Why?
|
| Histones | 1 | 2023 | 666 | 0.130 |
Why?
|
| Cytosol | 1 | 2018 | 213 | 0.130 |
Why?
|
| Logic | 1 | 2017 | 7 | 0.130 |
Why?
|
| Cell Proliferation | 1 | 2025 | 2514 | 0.130 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 113 | 0.130 |
Why?
|
| Flavonols | 1 | 2017 | 27 | 0.130 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 442 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 821 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 409 | 0.120 |
Why?
|
| Humans | 16 | 2025 | 145750 | 0.110 |
Why?
|
| Sulfhydryl Compounds | 1 | 2017 | 189 | 0.110 |
Why?
|
| Down Syndrome | 1 | 2022 | 525 | 0.110 |
Why?
|
| Animals | 6 | 2025 | 38100 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 926 | 0.090 |
Why?
|
| Lung | 1 | 2025 | 4116 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2025 | 2667 | 0.090 |
Why?
|
| Energy Metabolism | 1 | 2018 | 935 | 0.090 |
Why?
|
| Mitochondria | 1 | 2018 | 992 | 0.090 |
Why?
|
| Drug Design | 2 | 2022 | 175 | 0.080 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2020 | 194 | 0.070 |
Why?
|
| Adenosine Triphosphate | 2 | 2019 | 500 | 0.060 |
Why?
|
| Female | 5 | 2025 | 79025 | 0.060 |
Why?
|
| Coculture Techniques | 1 | 2025 | 247 | 0.050 |
Why?
|
| Mice | 4 | 2024 | 18357 | 0.050 |
Why?
|
| Poly ADP Ribosylation | 1 | 2023 | 10 | 0.050 |
Why?
|
| Apoptosis | 2 | 2024 | 2443 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2024 | 231 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2020 | 1454 | 0.050 |
Why?
|
| Autophagy | 1 | 2025 | 291 | 0.050 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2023 | 53 | 0.050 |
Why?
|
| Catalytic Domain | 1 | 2023 | 234 | 0.050 |
Why?
|
| Integrins | 1 | 2022 | 90 | 0.040 |
Why?
|
| Oncogenes | 1 | 2022 | 118 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 735 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 2020 | 83 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2025 | 1027 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2022 | 228 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 33 | 0.040 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2019 | 42 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2019 | 185 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2023 | 729 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 334 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2020 | 111 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2023 | 740 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 563 | 0.030 |
Why?
|
| A549 Cells | 1 | 2018 | 75 | 0.030 |
Why?
|
| Organoids | 1 | 2020 | 145 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 177 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 212 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 971 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 1368 | 0.030 |
Why?
|
| Photochemical Processes | 1 | 2017 | 103 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2017 | 487 | 0.030 |
Why?
|
| Transcriptome | 1 | 2022 | 1043 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1329 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2022 | 1359 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1969 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2022 | 4151 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2022 | 2051 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 1450 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 4569 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2020 | 2805 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2025 | 5223 | 0.020 |
Why?
|
| Oxygen | 1 | 2017 | 981 | 0.020 |
Why?
|